Parker CT, Thomas D. Reiter's syndrome and reactive arthritis. J Am Osteopath Assoc. 2000;100:101-104.
Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218-1227.
Toivanen A. Managing reactive arthritis. Rheumatology (Oxford). 2000;39:117-119.
Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum. 2010;62:1298-1307.
Colmegna I, Espinoza LR. Recent advances in reactive arthritis. Curr Rheumatol Rep. 2005;7:201-207.
1. Parker CT, Thomas D. Reiter's syndrome and reactive arthritis. J Am Osteopath Assoc. 2000;100:101-104.
2. Lu DW, Katz KA. Declining use of the eponym "Reiter's syndrome" in the medical literature, 1998-2003. J Am Acad Dermatol. 2005;53:720-723.
3. Braun J, Kingsley G, van der Heijde D, et al. On the difficulties of establishing a consensus on the definition of and diagnostic investigations of reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol. 2000;27:2185-2192.
4. Michet CJ, Machado EB, Ballard DJ, et al. Epidemiology of Reiter's syndrome in Rochester, Minnesota: 1950-1980. Arthritis Rheum. 1988;31:428-431.
5. Flores D, Marquez J, Garza M, et al. Reactive arthritis: newer developments. Rheum Dis Clin North Am. 2003;29:37-59.
6. Rudwaleit M, Richter S, Braun J, et al. Low incidence of reactive arthritis in children following a salmonella outbreak. Ann Rheum Dis. 2001;60:1055-1057.
7. Kvien TK, Glennas A, Melby G, et al. Reactive arthritis: incidence, triggering agents and clinical presentation. J Rheumatol. 1994;21:115-122.
8. Toivanen A, Toivanen P. Reactive arthritis. Best Pract Res Clin Rheumatol. 2004;18:689-703.
9. Rich E, Hook EW 3rd, Alarcon GS, et al. Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. Arthritis Rheum. 1996;39:1172-1177.
10. Carter JD, Rehman A, Guthrie JP, et al. Attack rate of Chlamydia-induced reactive arthritis and effect of the CCR5-Delta-32 mutation: a prospective analysis. J Rheumatol. 2013;40:1578-1582.
11. Eastmond CJ, Rennie JA, Reid TM. An outbreak of Campylobacter enteritis - a rheumatological followup survey. J Rheumatol. 1983;10:107-108.
12. Dworkin MS, Shoemaker PC, Goldoft MJ, et al. Reactive arthritis and Reiter's syndrome following an outbreak of gastroenteritis caused by Salmonella enteritidis. Clin Infect Dis. 2001;33:1010-1014.
13. Gerard HC, Branigan PJ, Schumacher HR Jr, et al. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol. 1998;25:734-742.
14. Gerard HC, Schumacher HR, El-Gabalawy H, et al. Chlamydia pneumoniae present in the human synovium are viable and metabolically active. Microb Pathog. 2000;29:17-24.
15. Granfors K, Jalkanen S, Toivanen P, et al. Bacterial lipopolysaccharide in synovial fluid cells in Shigella triggered reactive arthritis. J Rheumatol. 1992;19:500.
16. Gaston JS, Cox C, Granfors K. Clinical and experimental evidence for persistent Yersinia infections in reactive arthritis. Arthritis Rheum. 1999;42:2239-2242.
17. Braun J, Tuszewski M, Ehlers S, et al. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. J Rheumatol. 1997;24:1101-1105.
18. Nikkari S, Merilahti-Palo R, Saario R, et al. Yersinia-triggered reactive arthritis. Use of polymerase chain reaction and immunocytochemical staining in the detection of bacterial components from synovial specimens. Arthritis Rheum. 1992;35:682-687.
19. Nikkari S, Rantakokko K, Ekman P, et al. Salmonella-triggered reactive arthritis: use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. Arthritis Rheum. 1999;42:84-89.
20. Taylor-Robinson D, Gilroy CB, Thomas BJ, et al. Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet. 1992;340:81-82.
21. Viitanen AM, Arstila TP, Lahesmaa R, et al. Application of the polymerase chain reaction and immunofluorescence techniques to the detection of bacteria in Yersinia-triggered reactive arthritis. Arthritis Rheum. 1991;34:89-96.
22. Barth WF, Segal K. Reactive arthritis (Reiter's syndrome). Am Fam Physician. 1999;60:499-503, 507.
23. Rahman MU, Hudson AP, Schumacher HR Jr. Chlamydia and Reiter's syndrome (reactive arthritis). Rheum Dis Clin North Am. 1992;18:67-79.
24. Carter JD, Gerard HC, Espinoza LR, et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum. 2009;60:1311-1316.
25. Altekruse SF, Stern NJ, Fields PI, et al. Campylobacter jejuni - an emerging foodborne pathogen. Emerg Infect Dis. 1999;5:28-35.
26. Hannu T, Mattila L, Rautelin H, et al. Campylobacter-triggered reactive arthritis: a population-based study. Rheumatology (Oxford). 2002;41:312-318.
27. Hannu T, Kauppi M, Tuomala M, et al. Reactive arthritis following an outbreak of Campylobacter jejuni infection. J Rheumatol. 2004;31:528-530.
28. Buxton JA, Fyfe M, Berger S, et al. Reactive arthritis and other sequelae following sporadic Salmonella typhimurium infection in British Colombia, Canada: a case control study. J Rheumatol. 2002;29:2154-2158.
29. Hannu T, Mattila L, Siitonen A, et al. Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study. Ann Rheum Dis. 2005;64:594-598.
30. Hannu T, Mattila L, Nuorti JP, et al. Reactive arthritis after an outbreak of Yersinia pseudotuberculosis serotype O:3 infection. Ann Rheum Dis. 2003;62:866-869.
31. Press N, Fyfe M, Bowie W, et al. Clinical and microbiological follow-up of an outbreak of Yersinia pseudotuberculosis serotype Ib. Scand J Infect Dis. 2001;33:523-526.
32. Vasala M, Hallanvuo S, Ruuska P, et al. High frequency of reactive arthritis in adults after Yersinia pseudotuberculosis O:1 outbreak caused by contaminated grated carrots. Ann Rheum Dis. 2014;73:1793-1796.
33. Gerard HC, Whittum-Hudson JA, Schumacher HR, et al. Differential expression of three Chlamydia trachomatis hsp60-encoding genes in active vs. persistent infections. Microb Pathog. 2004;36:35-39.
34. Gracey E, Inman RD. Chlamydia-induced ReA: immune imbalances and persistent pathogens. Nat Rev Rheumatol. 2011;8:55-59.
35. Baillet AC, Rehaume L, Benham H, et al. High Chlamydia burden promotes TNF-dependent reactive arthritis in SKG mice. Arthritis Rheumatol. 2015;67:1535-1547.
36. Zugel U, Kaufmann SH. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev. 1999;12:19-39.
37. Gérard HC, Carter JD, Hudson AP. Chlamydia trachomatis is present and metabolically active during the remitting phase in synovial tissues from patients with chronic chlamydia-induced reactive arthritis. Am J Med Sci. 2013;346:22-25.
38. Morris D, Inman RD. Reactive arthritis: developments and challenges in diagnosis and treatment. Curr Rheumatol Rep. 2012;14:390-394.
39. Airenne S, Surcel HM, Tuukkanen J, et al. Chlamydia pneumoniae inhibits apoptosis in human epithelial and monocyte cell lines. Scand J Immunol. 2002;55:390-398.
40. Dean D, Powers VC. Persistent Chlamydia trachomatis infections resist apoptotic stimuli. Infect Immun. 2001;69:2442-2447.
41. Chen YJ, Li RN, Lin CH, et al. The role of monocytes and SLC11A1 polymorphisms in the pathogenesis of Chlamydia-induced reactive arthritis. Scand J Rheumatol. 2013;42:146-149.
42. Inman RD, Johnston ME, Hodge M, et al. Postdysenteric reactive arthritis: a clinical and immunogenetic study following an outbreak of salmonellosis. Arthritis Rheum. 1988;31:1377-1383.
43. Mattila L, Leirisalo-Repo M, Koskimies S, et al. Reactive arthritis following an outbreak of Salmonella infection in Finland. Br J Rheumatol. 1994;33:1136-1141.
44. Matilla L, Leirisalo-Repo M, Pelkonen P, et al. Reactive arthritis following an outbreak of Salmonella bovismorbificans infection. J Infect. 1998;36:289-295.
45. Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol. 2004;31:1973-1980.
46. Kvien TK, Gaston JS, Bardin T, et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double-blind, placebo controlled study. Ann Rheum Dis. 2004;63:1113-1119.
47. Dulphy N, Peyrat MA, Tieng V, et al. Common intra-articular T cell expansions in patients with reactive arthritis: identical beta-chain junctional sequences and cytotoxicity toward HLA-B27. J Immunol. 1999;162:3830-3839.
48. Popov I, Dela Cruz CS, Barber BH, et al. Breakdown of CTL tolerance to self HLA-B*2705 induced by exposure to Chlamydia trachomatis. J Immunol. 2002;169:4033-4038.
49. Alvarez-Navarro C, Cragnolini JJ, Dos Santos HG, et al. Novel HLA-B27-restricted epitopes from Chlamydia trachomatis generated upon endogenous processing of bacterial proteins suggest a role of molecular mimicry in reactive arthritis. J Biol Chem. 2013;288:25810-25825.
50. Saarinen M, Ekman P, Ikeda M, et al. Invasion of Salmonella into human intestinal epithelial cells is modulated by HLA-B27. Rheumatology (Oxford). 2002;41:651-657.
51. Kuipers JG, Bialowons A, Dollmann P, et al. The modulation of chlamydial replication by HLA-B27 depends on the cytoplasmic domain of HLA-B27. Clin Exp Rheumatol. 2001;19:47-52.
52. Keat AC, Maini RN, Pegrum GD, et al. The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis. Q J Med. 1979;48:323-342.
53. Sieper J, Rudwaleit M, Braun J, et al. Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Arthritis Rheum. 2002;46:319-327.
54. British Association for Sexual Health and HIV. United Kingdom national guideline on the management of sexually acquired reactive arthritis. January 2008. http://www.bashh.org (last accessed 21 March 2016).
55. Tuuminen T, Lounamo K, Leirisalo-Repo M. A review of serological tests to assist diagnosis of reactive arthritis: critical appraisal on methodologies. Front Immunol. 2013;4:418.
56. Martel W, Braunstein EM, Borlaza G, et al. Radiologic features of Reiter disease. Radiology. 1979;132:1-10.
57. Russell AS, Davis P, Percy JS, et al. The sacroiliitis of acute Reiter's syndrome. J Rheumatol. 1977;4:293-296.
58. Ozgul A, Dede I, Taskaynatan MA, et al. Clinical presentations of chlamydial and non-chlamydial reactive arthritis. Rheumatol Int. 2006;26:879-885.
59. Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic. 1990;57:85-89.
60. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218-1227.
61. Toivanen A. Managing reactive arthritis. Rheumatology (Oxford). 2000;39:117-119.
62. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veteran's Affairs Cooperative Study. Arthritis Rheum. 1996;39:2021-2027.
63. Kuuliala A, Julkunen H, Paimela L, et al. Double-blind, randomized, placebo-controlled study of three-month treatment with the combination of ofloxacin and roxithromycin in recent-onset reactive arthritis. Rheumatol Int. 2013;33:2723-2729.
64. Lauhio A, Leirisalo-Repo M, Lahdevirta J, et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum. 1991;34:6-14.
65. Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum. 2010;62:1298-1307.
66. Barber CE, Kim J, Inman RD, et al. Antibiotics for treatment of reactive arthritis: a systematic review and meta-analysis. J Rheumatol. 2013;40:916-928.
67. Flagg SD, Meador R, Hsia E, et al. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum. 2005;53:613-617.
68. Oili KS, Niinisalo H, Korpilahde T, et al. Treatment of reactive arthritis with infliximab. Scand J Rheumatol. 2003;32:122-124.
69. Haibel H, Brandt J, Rudwaleit M, et al. Therapy of chronic enteral reactive arthritis with infliximab. Ann Rheum Dis. 2003;62:ABO380.
70. Meyer A, Chatelus E, Wendling D, et al. Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum. 2011;63:1274-1280.
71. Rihl M, Gu J, Baeten D, et al. Alpha beta but not gamma delta T cell clones in synovial fluids of patients with reactive arthritis show active transcription of tumour necrosis factor alpha and interferon gamma. Ann Rheum Dis. 2004;63:1673-1676.
72. Braun J, Yin Z, Spiller I, et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum. 1999;42:2039-2044.
73. Thiel A, Wu P, Lauster R, et al. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis Rheum. 2000;43:2834-2842.
74. Yin Z, Braun J, Neure L, et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum. 1997;40:1788-1797.
75. Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev. 2004;17:348-369.
76. Ishihara T, Aga M, Hino K, et al. Inhibition of Chlamydia trachomatis growth by human interferon-alpha: mechanisms and synergistic effect with interferon-gamma and tumor necrosis factor-alpha. Biomed Res. 2005;26:179-185.
77. Perry LL, Feilzer K, Caldwell HD. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J Immunol. 1997;158:3344-3352.
78. Takano R, Yamaguchi H, Sugimoto S, et al. Cytokine response of lymphocytes persistent infected with Chlamydia pneumoniae. Curr Microbiol. 2005;50:160-166.
79. Sieper J, Fendler C, Laitko S, et al. No benefit of long-term ciprofloxacin in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum. 1999;42:1386-1396.
80. Putschky N, Pott HG, Kuipers JG, et al. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: A prospective, double-blind trial. Ann Rheum Dis. 2006;65:1521-1524.
81. Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, et al. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother. 2000;44:3288-3297.
82. Dreses-Werringloer U, Padubrin I, Zeidler H, et al. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob Agents Chemother. 2001;45:3001-3008.
83. Morrissey I, Salman H, Bakker S, et al. Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J Antimicrob Chemother. 2002;49:757-761.
84. Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136:896-907.
85. Benchaala I, Mishra MK, Wykes SM, et al. Folate-functionalized dendrimers for targeting Chlamydia-infected tissues in a mouse model of reactive arthritis. Int J Pharm. 2014;466:258-265.
86. Colmegna I, Espinoza LR. Recent advances in reactive arthritis. Curr Rheumatol Rep. 2005;7:201-207.
87. Leirisalo-Repo M, Helenius P, Hannu T, et al. Long-term prognosis of reactive salmonella arthritis. Ann Rheum Dis. 1997;56:516-520.
88. Yli-Kerttula T, Tertti R, Toivanen A. Ten-year follow up study of patients from a Yersinia pseudotuberculosis III outbreak. Clin Exp Rheumatol. 1995;13:333-337.
89. Rihl M, Klos A, Kohler L, et al. Infection and musculoskeletal conditions: reactive arthritis. Best Pract Res Clin Rheumatol. 2006;20:1119-1137.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台